Muneer Satter

Director at Alzheon.

Framingham, MA
Alzheon

Raised on Alzheon filings

$126.3M

of $150M offered across 1 Form D filing

Form D filings: 1
Teammates: 1
Last filing: Feb 10, 2025

Company

Biotech · Framingham, MA

Oral Alzheimer's drug targeting amyloid oligomers

Oral Alzheimer's drug targeting amyloid oligomers

Investors: 76
Still open: $23.7M

Investors: 76
Sector: Biotech
HQ: Framingham, MA

Alzheon filings

Alzheon Form D filings
Filed	Security	Sold of offered	Filing
Feb 10, 2025	Equity	$126.3M/ $150M	Form D/A

EquityFiled Feb 10, 2025Form D/A
$126.3M/ $150M

Works with

Also named on Alzheon filings

Martin Tolar, M.D., Ph.D.President and Chief Executive Officer, Form D signerForm D signer